ClinicalTrials.gg
CompletedNCT02005471MURANOUpdated Oct 17, 2023Results posted

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Bendamustine and Venetoclax in Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Completed at 111 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
389
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 69
389 · median 72
Started
2014
with 5 others
Phase 3
15 of 69
3 open now
Registered
6th of 69
by date
Lead sponsor
3 of 69
Hoffmann-La Roche

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 6 that started in 2014, is one of 15 in phase 3, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of CLL per diagnostic criteria for CLL per the international workshop on chronic lymphocytic leukemia (iwCLL) guidelines
  • Previously treated with 1-3 (example: completed greater than or equal to [>/=] 2 treatment cycles per therapy), including at least one standard chemotherapy-containing regimen
  • Participants previously treated with bendamustine only if their duration of response was >/= 24 months
  • (ECOG) performance score of less than or equal to (\</=) 1
  • Adequate bone marrow function
  • Adequate renal and hepatic function
  • Participants must use effective throughout study until at least 30 days after study treatment or 1 year after rituximab treatment, whichever is later; female participants must not be pregnant or breast-feeding
  • For participants with the 17p deletion, previously treated with 1-3 lines of therapy, including at least one prior standard chemotherapy-containing regimen or at least one prior alemtuzumab-containing therapy

Inclusion Criteria R/C Substudy:

  • Participants randomized to Arm A or Arm B with a confirmed disease progression of CLL per iwCLL criteria
  • Participants who have not received new anti-CLL therapy following disease progression in Arm A or Arm B
  • Adequate renal and hepatic function per laboratory reference range

Exclusion Criteria:

  • Transformation of CLL to aggressive non-Hodgkin lymphoma or central nervous system (CNS) involvement by CLL
  • Undergone an allogenic stem cell transplant
  • A history of significant renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular or hepatic disease
  • or C or known (HIV) positive
  • Receiving warfarin treatment
  • Received an anti-CLL monoclonal antibody within 8 weeks prior to the first dose of study drug
  • Received any anti-cancer or therapy within 28 days prior to the first dose of study drug or has not recovered to less than Grade 2 adverse effect(s)/toxicity(ies) of any previous therapy
  • Received cytochrome P450 3A4 () inhibitors (such as fluconazole, ketoconazole and clarithromycin) or inducers (such as rifampin, carbamazapine, phenytoin, St. John's Wort) within 7 days prior to the first dose of venetoclax
  • History of prior venetoclax treatment
  • Participants with another cancer, history of another cancer considered uncured on in complete remission for \<5 years, or currently under treatment for another suspected cancer except non-melanoma skin cancer or carcinoma in situ of the cervix that has been treated or excised and is considered resolved
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Other clinically significant uncontrolled condition(s) including, but not limited to, systemic infection (viral, bacterial or fungal)
  • Vaccination with a within 28 days prior to randomization
  • Consumed grapefruit or grapefruit products, seville oranges (including marmalade containing seville oranges), or star fruit within 3 days prior to the first dose of study treatment
  • A cardiovascular disability status of Class >/=3. Class 3 is defined as cardiac disease in which participants are comfortable at rest but have marked limitation of physical activity due to fatigue, palpitations, dyspnea, or anginal pain
  • Major surgery within 30 days prior to the first dose of study treatment
  • A participant who is pregnant or breastfeeding
  • Known allergy to both xanthine oxidase inhibitors and rasburicase

Exclusion Criteria R/C Substudy:

  • Transformation of CLL to aggressive NHL (e.g., Richter's transformation, prolymphocytic leukemia, or DLBCL) or CNS involvement by CLL
  • Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)
  • Development of other since enrollment into the study, with the exception of curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Uncontrolled hemolytic anemia or immune thrombocytopenia
  • History of severe (i.e., requiring permanent discontinuation of prior rituximab therapy) prior allergic or anaphylactic reactions to rituximab
  • Known HIV positivity
  • Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HbsAg] serology)
  • Positive test results for virus (HCV; HCV antibody serology testing)
  • Requires the use of warfarin (due to potential drug interactions that may potentially increase the exposure of warfarin)
  • Has not recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(ies) of any previous therapy
  • Received potent CYP3A4 inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within 7 days prior to the first dose of study treatment
  • Received potent CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, St. John's wort) within 7 days prior to the first dose of study treatment
  • Consumed grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study treatment
  • A cardiovascular disability status of New York Heart Association Class >/= 3
  • A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the participants's participation in this study or interpretation of study outcomes
  • Major surgery within 30 days prior to the first dose of study treatment
  • A participant who is pregnant or breastfeeding
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Known allergy to both xanthine oxidase inhibitors and rasburicase
  • Vaccination with a live vaccine within 28 days prior to randomization
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
389 participants (actual)

Study arms

  • Active comparator
    Bendamustine + Rituximab

    Participants will receive bendamustine 70 milligrams per meter square (mg/m\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.

    Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Venetoclax + Rituximab

    Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.

    Drug: Venetoclax · Drug: Rituximab

  • Experimental
    Bendamustine + Rituximab Crossover Substudy

    Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.

    Drug: Venetoclax · Drug: Rituximab

  • Experimental
    Venetoclax + Rituximab Re-Treatment

    Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.

    Drug: Venetoclax · Drug: Rituximab

Interventions

  • Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.

  • Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first. R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy.

    Also known as: GDC-0199, ABT-199

  • Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6. R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death

    Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (greater than \[\>\] 1.5 centimeters \[cm\]); unequivocal progression of non-target lesion; an increase of greater than or equal to (\>/=) 50 percent (%) compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000 per microliter (mcL), or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 grams per deciliter (g/dL) or to less than \[\<\] 10 g/dL. Percentages are rounded off.

    Time frame: Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)

  2. Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines

    PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% confidence interval (CI) was computed using method of Brookmeyer and Crowley.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)

Secondary outcomes

  1. Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines

    Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)

  2. PFS as Assessed by the IRC Using Standard iwCLL Guidelines

    PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)

  3. Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test

    Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)

  4. PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

    PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)

  5. Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

    Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)

  6. PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

    PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.

    Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)

  7. Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines

    Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off.

    Time frame: Baseline up to approximately 8 years 5 months

  8. Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines

    Response was assessed by IRC according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.No new IRC data was generated post primary analysis.

    Time frame: Baseline up to last FUV (up to approximately 3 years)

  9. Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines

    Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.

    Time frame: End of combination treatment response (EoCTR) visit (8 to 12 weeks after Cycle [C] 6 Day [1]); Cycle length = 28 days

  10. Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines

    Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method.

    Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days

  11. Percentage of Participants Who Died

    Percentage of participants who died from any cause, during the study, was reported. Percentage is rounded off.

    Time frame: Baseline up to approximately 8 years 5 months

  12. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

    Time frame: Baseline up to approximately 8 years 5 months

  13. Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines

    Percentage of participants with PD/relapse, death from any cause, or start of a new non-protocol-specified anti-CLL therapy as assessed by the investigator, during the study, was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.

    Time frame: Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)

  14. Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines

    EFS was defined as the time from date of randomization until the date of PD/relapse, start of a new non-protocol-specified anti-CLL therapy, or death from any cause, whichever occurred first, as assessed by the investigator. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without any of the specified event at the time of analysis were censored at the date of last adequate response assessment. In case of no post-baseline response assessment, participants were censored at the randomization date. The median EFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

    Time frame: Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)

  15. Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines

    Percentage of participants with PD as assessed by the investigator according to the iwCLL guidelines or death from any cause during the study was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint. Percentage is rounded off.

    Time frame: From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)

  16. Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines

    DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint.

    Time frame: From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)

  17. Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator

    Percentage of participants with start of new non-protocol-specified anti-CLL therapy, as assessed by the investigator, or death from any cause, during the study, was reported. Percentage is rounded off.

    Time frame: Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)

  18. Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator

    TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

    Time frame: Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)

  19. Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood

    MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off.

    Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days

  20. Percentage of Participants With MRD Negativity in Bone Marrow

    MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.

    Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days

  21. Plasma Venetoclax Concentrations

    Time frame: Pre-dose (0 hour, anytime before venetoclax administration) and 4 hours post-dose on D1 of Cycles 1 and 4; Cycle length = 28 days

  22. Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores

    MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL).

    Time frame: Baseline, Days 1, 8, and 15 of Cycles 1, 2, and 3; Cycle length = 28 days

  23. Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score

    EORTC QLQ-C30 is a validated self-report measure consisting of 30 questions incorporated into 5 functional scales (Physical, Role, Cognitive, Emotional, and Social), 3 symptom scales (fatigue, pain, nausea, and vomiting), a global health status/global QoL scale, and single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea). Most questions used 4-point scale (1='Not at all' to 4='Very much'), while 2 questions used 7-point scale (1='very poor' to 7='Excellent'). Scores were averaged, transformed to 0-100 scale; where higher score for functional scales=poor level of functioning; higher score for global health status/global QoL=better HRQoL.

    Time frame: Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days

  24. Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score

    The EORTC QLQ-CLL16 module is designed for participants with Stage 0 to Stage 4 CLL. It is composed of 16 questions and there are four multi-item scales on Fatigue (2 items), Treatment-related side effects (TRSE, 4 items), Disease-related symptoms (DRS, 4 items), and Infection (4 items); and two single-item scales on social activities and future health worries. Multi-item scales score are reported and the total score for each multi-item scale was transformed to result in a total score range of 0 to 100, where higher score = poor HRQoL.

    Time frame: Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days

  25. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE, v4.0)

    Time frame: From signing of informed consent form up to approximately 8 years 5 months

  26. Number of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs)

    An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A SAE is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. TLS and IRRs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening; Grade 5 = Death. A higher grade indicates a worse outcome.

    Time frame: From signing of informed consent form up to approximately 8 years 5 months

Other outcomes

  1. Change From Baseline in Lymphocyte Subset Counts at Specified Time Points

    Time frame: Baseline, C4D14-28, Study Treatment Completion/Early Withdrawal (STC/EW, up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and at FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days

07

Results

Posted Oct 1, 2018

Participant flow

A total 389 participants took part in the study across 109 investigative sites in 20 countries i.e., Korea, Taiwan, Australia, New Zealand, Czech Republic, Hungary, Poland, Russia, Canada, United States of America, Austria, Belgium, Germany, Denmark, Spain, France, United Kingdom, Italy, Netherlands and Sweden from 17 March 2014 to 03 August 2022. The trial consisted of a main study and an optional Retreatment/Crossover (R/C) sub study.

Main Study
Participant flow — Main Study
MilestoneBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyBendamustine + Rituximab Crossover SubstudyVenetoclax + Rituximab Re-Treatment Substudy
Started19519400
Safety evaluable (se) population18819400
Completed7111800
Not completed1247600
Withdrew: Adverse event0100
Withdrew: Death835200
Withdrew: Lost to follow-up4500
Withdrew: Physician decision3100
Withdrew: Withdrawal by subject261100
Withdrew: Reason not specified0600
Withdrew: Randomized but not dosed8000
Re-Treatment/Crossover (R/C) Substudy
Participant flow — Re-Treatment/Crossover (R/C) Substudy
MilestoneBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyBendamustine + Rituximab Crossover SubstudyVenetoclax + Rituximab Re-Treatment Substudy
Started00925
Completed00715
Not completed00210
Withdrew: Withdrawal by subject0001
Withdrew: Lost to follow-up0011
Withdrew: Death0018

Outcome measures

PrimaryPercentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death

Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (greater than \[\>\] 1.5 centimeters \[cm\]); unequivocal progression of non-target lesion; an increase of greater than or equal to (\>/=) 50 percent (%) compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000 per microliter (mcL), or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 grams per deciliter (g/dL) or to less than \[\<\] 10 g/dL. Percentages are rounded off.

Time frame:
Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death88.770.1
PrimaryProgression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines

PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% confidence interval (CI) was computed using method of Brookmeyer and Crowley.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Median · months
Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines17.0 (15.5 to 21.7)54.7 (52.3 to 59.9)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.23 · 95% CI 0.18 to 0.29Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.25 · 95% CI 0.19 to 0.31Hazard ratio was estimated by Cox regression model
SecondaryPercentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines

Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines54.418.0
SecondaryPFS as Assessed by the IRC Using Standard iwCLL Guidelines

PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Reported as:
Median · months
PFS as Assessed by the IRC Using Standard iwCLL Guidelines
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
PFS as Assessed by the IRC Using Standard iwCLL Guidelines18.1 (15.8 to 22.3)NA (NA to NA)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.19 · 95% CI 0.13 to 0.28Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.20 · 95% CI 0.14 to 0.30Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test

Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test
percentage of participantsBendamustine + Rituximab 17p Del. PopulationVenetoclax + Rituximab 17p Del. Population
Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test80.480.4
SecondaryPFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Median · months
PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
monthsBendamustine + Rituximab 17p Del. PopulationVenetoclax + Rituximab 17p Del. Population
PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test15.4 (10.0 to 21.0)47.9 (37.4 to 59.9)
Statistical analysis
  • Bendamustine + Rituximab 17p Del. Population vs Venetoclax + Rituximab 17p Del. Population · Log Rank · p = <.0001 · Hazard ratio (hr): 0.35 · 95% CI 0.21 to 0.57Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab 17p Del. Population vs Venetoclax + Rituximab 17p Del. Population · Log Rank · p = <.0001 · Hazard ratio (hr): 0.35 · 95% CI 0.22 to 0.56Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
percentage of participantsBendamustine + Rituximab 17p Del. PopulationVenetoclax + Rituximab 17p Del. Population
Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test47.819.6
SecondaryPFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test

PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.

Time frame:
Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Reported as:
Median · months
PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
monthsBendamustine + Rituximab 17p Del. PopulationVenetoclax + Rituximab 17p Del. Population
PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test16.1 (13.6 to 22.3)NA (27.6 to NA)
Statistical analysis
  • Bendamustine + Rituximab 17p Del. Population vs Venetoclax + Rituximab 17p Del. Population · Log Rank · p = <.0001 · Hazard ratio (hr): 0.21 · 95% CI 0.09 to 0.49Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab 17p Del. Population vs Venetoclax + Rituximab 17p Del. Population · Log Rank · p = <.0001 · Hazard ratio (hr): 0.21 · 95% CI 0.09 to 0.46Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines

Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off.

Time frame:
Baseline up to approximately 8 years 5 months
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
CR8.2 (4.76 to 12.98)26.3 (20.24 to 33.07)
CRi0.5 (0.01 to 2.82)1.5 (0.32 to 4.45)
nPR6.2 (3.22 to 10.50)3.6 (1.46 to 7.29)
PR52.8 (45.56 to 59.99)61.9 (54.62 to 68.72)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Cochran-Mantel-Haenszel · p = <.0001 · Difference in response rates: 25.61 · 95% CI 17.88 to 33.3395% CI for rates were constructed using Pearson- Clopper method. 95% CI for difference in rates were constructed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 7.81 · 95% CI 3.97 to 15.37OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPercentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines

Response was assessed by IRC according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.No new IRC data was generated post primary analysis.

Time frame:
Baseline up to last FUV (up to approximately 3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines67.7 (60.64 to 74.20)93.3 (88.81 to 96.38)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Cochran-Mantel-Haenszel · p = <.0001 · Difference in response rates: 25.61 · 95% CI 17.88 to 33.3395% CI for rates were constructed using Pearson- Clopper method. 95% CI for difference in rates were constructed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 7.81 · 95% CI 3.97 to 15.37OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPercentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines

Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.

Time frame:
End of combination treatment response (EoCTR) visit (8 to 12 weeks after Cycle [C] 6 Day [1]); Cycle length = 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines63.1 (55.89 to 69.86)88.1 (82.74 to 92.33)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Cochran-Mantel-Haenszel · p = <.0001 · Difference in response rates: 25.07 · 95% CI 16.63 to 33.51The 95% CI was computed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 4.59 · 95% CI 2.68 to 7.88OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPercentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines

Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method.

Time frame:
EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines62.6 (55.37 to 69.37)87.1 (81.57 to 91.48)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Cochran-Mantel-Haenszel · p = <.0001 · Difference in response rates: 24.55 · 95% CI 16.00 to 33.10The 95% CI was computed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 4.59 · 95% CI 2.68 to 7.85OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPercentage of Participants Who Died

Percentage of participants who died from any cause, during the study, was reported. Percentage is rounded off.

Time frame:
Baseline up to approximately 8 years 5 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants Who Died43.130.9
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

Time frame:
Baseline up to approximately 8 years 5 months
Reported as:
Median · months
Overall Survival (OS)
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Overall Survival (OS)87.8 (70.1 to NA)NA (NA to NA)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.53 · 95% CI 0.37 to 0.74Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = 0.0003 · Hazard ratio (hr): 0.54 · 95% CI 0.39 to 0.76Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines

Percentage of participants with PD/relapse, death from any cause, or start of a new non-protocol-specified anti-CLL therapy as assessed by the investigator, during the study, was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.

Time frame:
Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines89.271.1
SecondaryEvent-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines

EFS was defined as the time from date of randomization until the date of PD/relapse, start of a new non-protocol-specified anti-CLL therapy, or death from any cause, whichever occurred first, as assessed by the investigator. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without any of the specified event at the time of analysis were censored at the date of last adequate response assessment. In case of no post-baseline response assessment, participants were censored at the randomization date. The median EFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

Time frame:
Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)
Reported as:
Median · months
Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines16.4 (14.2 to 21.0)53.7 (48.5 to 59.3)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.22 · 95% CI 0.17 to 0.29Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.25 · 95% CI 0.19 to 0.31Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines

Percentage of participants with PD as assessed by the investigator according to the iwCLL guidelines or death from any cause during the study was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint. Percentage is rounded off.

Time frame:
From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines95.568.5
SecondaryDuration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines

DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint.

Time frame:
From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Median · months
Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines19.1 (16.1 to 23.6)53.6 (49.1 to 57.0)
SecondaryPercentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator

Percentage of participants with start of new non-protocol-specified anti-CLL therapy, as assessed by the investigator, or death from any cause, during the study, was reported. Percentage is rounded off.

Time frame:
Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator81.562.4
SecondaryTime to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator

TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.

Time frame:
Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)
Reported as:
Median · months
Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator
monthsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator24.0 (20.7 to 29.5)63.0 (56.1 to 73.6)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.30 · 95% CI 0.23 to 0.39Hazard ratio was estimated by Cox regression model.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Log Rank · p = <.0001 · Hazard ratio (hr): 0.32 · 95% CI 0.25 to 0.41Hazard ratio was estimated by Cox regression model.
SecondaryPercentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood

MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off.

Time frame:
EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood13.3 (8.90 to 18.92)62.4 (55.15 to 69.21)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Chi-squared · p = <.0001 · Difference in mrd negativity rates: 49.04 · 95% CI 40.44 to 57.64The 95% CI was computed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 10.77 · 95% CI 6.50 to 17.85OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPercentage of Participants With MRD Negativity in Bone Marrow

MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.

Time frame:
EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Reported as:
Number · percentage of participants
Percentage of Participants With MRD Negativity in Bone Marrow
percentage of participantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Percentage of Participants With MRD Negativity in Bone Marrow1.0 (0.12 to 3.66)14.4 (9.81 to 20.18)
Statistical analysis
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Chi-squared · p = <.0001 · Difference in mrd negative rates: 13.41 · 95% CI 7.99 to 18.82The 95% CI was computed using Anderson-Hauck method.
  • Bendamustine + Rituximab Main Study vs Venetoclax + Rituximab Main Study · Odds ratio (or): 16.28 · 95% CI 3.82 to 69.35OR was estimated using logistic regression model. The 95% CI was computed using Wald test.
SecondaryPlasma Venetoclax Concentrations
Time frame:
Pre-dose (0 hour, anytime before venetoclax administration) and 4 hours post-dose on D1 of Cycles 1 and 4; Cycle length = 28 days
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Plasma Venetoclax Concentrations
micrograms per milliliter (mcg/mL)Venetoclax + Rituximab Main Study
C1D1, Pre-dose0.626 ± 0.540
C1D1, 4 hours Post-Dose1.34 ± 0.881
C4D1, Pre-dose0.681 ± 0.745
C4D1, 4 hours Post-Dose1.34 ± 0.905
SecondaryChange From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores

MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL).

Time frame:
Baseline, Days 1, 8, and 15 of Cycles 1, 2, and 3; Cycle length = 28 days
Reported as:
Mean · units on a scale
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores
units on a scaleBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Baseline; Mean core symptom severity1.76 ± 1.551.55 ± 1.31
Change at C1D1; Mean core symptom severity0.00 ± 0.00-0.08 ± 0.98
Change at C1D8; Mean core symptom severity0.26 ± 1.34-0.30 ± 0.84
Change at C1D15; Mean core symptom severity0.00 ± 1.31-0.27 ± 0.93
Change at C2D1; Mean core symptom severity-0.23 ± 1.30-0.33 ± 0.91
Change at C2D8; Mean core symptom severity0.17 ± 1.59-0.45 ± 0.91
Change at C2D15; Mean core symptom severity-0.13 ± 1.53-0.53 ± 0.90
Change at C3D1; Mean core symptom severity-0.26 ± 1.60-0.40 ± 1.13
Change at C3D8; Mean core symptom severity-0.13 ± 1.63-0.66 ± 1.20
Change at C3D15; Mean core symptom severity-0.42 ± 1.52-0.53 ± 1.05
Baseline; Mean module symptom severity1.60 ± 1.461.57 ± 1.11
Change at C1D1; Mean module symptom severity0.00 ± 0.00-0.19 ± 0.96
Change at C1D8; Mean module symptom severity-0.22 ± 1.40-0.53 ± 0.96
Change at C1D15; Mean module symptom severity-0.43 ± 1.51-0.73 ± 1.13
Change at C2D1; Mean module symptom severity-0.49 ± 1.46-0.65 ± 0.92
Change at C2D8; Mean module symptom severity-0.46 ± 1.63-0.77 ± 0.87
Change at C2D15; Mean module symptom severity-0.69 ± 1.47-0.94 ± 0.93
Change at C3D1; Mean module symptom severity-0.65 ± 1.48-0.81 ± 0.97
Change at C3D8; Mean module symptom severity-0.51 ± 1.58-0.83 ± 0.97
Change at C3D15; Mean module symptom severity-0.83 ± 1.51-0.92 ± 0.97
Baseline; Mean interference1.81 ± 2.051.90 ± 2.25
Change at C1D1; Mean interference0.00 ± 0.00-0.13 ± 1.49
Change at C1D8; Mean interference0.45 ± 1.78-0.29 ± 2.14
Change at C1D15; Mean interference0.36 ± 1.850.01 ± 2.04
Change at C2D1; Mean interference0.01 ± 1.73-0.34 ± 1.78
Change at C2D8; Mean interference0.58 ± 2.20-0.58 ± 1.81
Change at C2D15; Mean interference0.06 ± 1.84-0.64 ± 1.59
Change at C3D1; Mean interference-0.02 ± 2.02-0.73 ± 2.06
Change at C3D8; Mean interference0.15 ± 1.91-0.82 ± 2.09
Change at C3D15; Mean interference-0.07 ± 2.01-0.55 ± 2.18
SecondaryChange From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score

EORTC QLQ-C30 is a validated self-report measure consisting of 30 questions incorporated into 5 functional scales (Physical, Role, Cognitive, Emotional, and Social), 3 symptom scales (fatigue, pain, nausea, and vomiting), a global health status/global QoL scale, and single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea). Most questions used 4-point scale (1='Not at all' to 4='Very much'), while 2 questions used 7-point scale (1='very poor' to 7='Excellent'). Scores were averaged, transformed to 0-100 scale; where higher score for functional scales=poor level of functioning; higher score for global health status/global QoL=better HRQoL.

Time frame:
Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days
Reported as:
Mean · units on a scale
Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score
units on a scaleBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Baseline; Physical functioning82.59 ± 17.4683.77 ± 15.27
Change at C1D1; Physical functioning0.0 ± 0.01.39 ± 12.90
Change at C2D1; Physical functioning0.31 ± 15.812.99 ± 12.83
Change at C3D1; Physical functioning0.22 ± 16.431.46 ± 14.76
Change at C4D1; Physical functioning2.11 ± 14.955.54 ± 14.17
Change at C5D1; Physical functioning2.44 ± 18.194.62 ± 15.27
Change at C6D1; Physical functioning2.25 ± 16.824.51 ± 16.59
Change at STC/EW; Physical functioning1.68 ± 18.764.53 ± 16.04
Change at EoCTR; Physical functioning2.92 ± 18.034.34 ± 16.12
Change at FUV1; Physical functioning2.27 ± 18.863.81 ± 16.27
Change at FUV2; Physical functioning2.40 ± 19.212.75 ± 17.17
Change at FUV3; Physical functioning2.54 ± 17.833.44 ± 17.31
Change at FUV4; Physical functioning4.74 ± 20.140.85 ± 21.06
Change at FUV5; Physical functioning1.90 ± 17.68-1.75 ± 19.35
Change at FUV6; Physical functioning-1.41 ± 15.341.33 ± 5.58
Change at FUV7; Physical functioning-3.08 ± 11.740.00
Change at FUV8; Physical functioning-9.33 ± 23.380.00
Change at FUV9; Physical functioning-10.00 ± 33.0—
Baseline; Role functioning78.25 ± 25.6783.82 ± 21.00
Change at C1D1; Role functioning0.0 ± 0.0-1.74 ± 23.23
Change at C2D1; Role functioning-1.26 ± 27.452.49 ± 23.07
Change at C3D1; Role functioning-0.10 ± 29.641.82 ± 26.08
Change at C4D1; Role functioning0.87 ± 29.015.13 ± 22.03
Change at C5D1; Role functioning0.45 ± 30.754.36 ± 23.44
Change at C6D1; Role functioning0.70 ± 29.921.79 ± 25.71
Change at STC/EW; Role functioning-0.41 ± 32.912.60 ± 25.58
Change at EoCTR; Role functioning3.26 ± 29.952.12 ± 26.69
Change at FUV1; Role functioning2.93 ± 32.312.65 ± 27.47
Change at FUV2; Role functioning3.07 ± 32.63-1.85 ± 31.84
Change at FUV3; Role functioning5.26 ± 31.161.88 ± 28.17
Change at FUV4; Role functioning5.41 ± 33.16-0.35 ± 30.39
Change at FUV5; Role functioning2.34 ± 29.791.75 ± 34.20
Change at FUV6; Role functioning-4.04 ± 27.01-13.33 ± 32.06
Change at FUV7; Role functioning2.56 ± 29.54-16.67
Change at FUV8; Role functioning0.00 ± 23.5716.67
Change at FUV9; Role functioning-16.67 ± 23.57—
Baseline; Emotional functioning78.98 ± 22.4782.13 ± 15.80
Change at C1D1; Emotional functioning0.0 ± 0.04.35 ± 15.17
Change at C2D1; Emotional functioning2.24 ± 20.075.60 ± 14.68
Change at C3D1; Emotional functioning2.99 ± 20.065.34 ± 19.09
Change at C4D1; Emotional functioning2.61 ± 18.354.19 ± 15.45
Change at C5D1; Emotional functioning1.14 ± 18.793.97 ± 17.37
Change at C6D1; Emotional functioning2.06 ± 18.743.08 ± 17.96
Change at STC/EW; Emotional functioning2.43 ± 20.615.34 ± 18.69
Change at EoCTR; Emotional functioning2.58 ± 19.453.49 ± 17.83
Change at FUV1; Emotional functioning3.49 ± 20.914.37 ± 18.50
Change at FUV2; Emotional functioning4.39 ± 20.330.66 ± 21.02
Change at FUV3; Emotional functioning0.63 ± 19.972.82 ± 17.66
Change at FUV4; Emotional functioning4.82 ± 19.731.95 ± 18.41
Change at FUV5; Emotional functioning3.13 ± 17.952.63 ± 20.61
Change at FUV6; Emotional functioning2.27 ± 21.785.00 ± 17.28
Change at FUV7; Emotional functioning5.77 ± 17.48-8.33
Change at FUV8; Emotional functioning3.33 ± 28.010.00
Change at FUV9; Emotional functioning-16.67 ± 11.79—
Baseline; Cognitive functioning86.55 ± 16.7889.86 ± 14.91
Change at C1D1; Cognitive functioning0.0 ± 0.0-1.24 ± 14.01
Change at C2D1; Cognitive functioning-0.19 ± 15.340.25 ± 14.06
Change at C3D1; Cognitive functioning-0.32 ± 16.34-1.56 ± 17.50
Change at C4D1; Cognitive functioning-1.54 ± 17.41-0.26 ± 17.05
Change at C5D1; Cognitive functioning-1.94 ± 18.10-0.26 ± 14.28
Change at C6D1; Cognitive functioning-2.68 ± 16.97-0.77 ± 15.98
Change at STC/EW; Cognitive functioning-2.19 ± 17.651.04 ± 18.28
Change at EoCTR; Cognitive functioning-2.23 ± 18.11-0.27 ± 16.94
Change at FUV1; Cognitive functioning-2.02 ± 17.21-0.26 ± 15.98
Change at FUV2; Cognitive functioning1.32 ± 16.16-2.38 ± 18.17
Change at FUV3; Cognitive functioning-1.63 ± 14.84-2.96 ± 18.24
Change at FUV4; Cognitive functioning0.44 ± 17.63-1.77 ± 19.11
Change at FUV5; Cognitive functioning-1.49 ± 15.66-6.14 ± 21.67
Change at FUV6; Cognitive functioning-0.51 ± 14.720.00 ± 0.00
Change at FUV7; Cognitive functioning-1.28 ± 14.370.00
Change at FUV8; Cognitive functioning0.00 ± 23.570.00
Change at FUV9; Cognitive functioning16.67 ± 23.57—
Baseline; Social functioning82.48 ± 22.0685.51 ± 21.18
Change at C1D1; Social functioning0.0 ± 0.0-1.74 ± 19.92
Change at C2D1; Social functioning-2.44 ± 21.440.25 ± 18.46
Change at C3D1; Social functioning-2.32 ± 22.613.65 ± 25.45
Change at C4D1; Social functioning-0.55 ± 22.154.62 ± 20.09
Change at C5D1; Social functioning-5.48 ± 26.492.56 ± 20.46
Change at C6D1; Social functioning-5.13 ± 24.803.85 ± 24.61
Change at STC/EW; Social functioning-4.06 ± 27.711.04 ± 19.22
Change at EoCTR; Social functioning-0.47 ± 24.951.88 ± 20.49
Change at FUV1; Social functioning-1.08 ± 26.091.59 ± 24.27
Change at FUV2; Social functioning0.58 ± 24.681.32 ± 27.97
Change at FUV3; Social functioning-0.91 ± 24.001.88 ± 25.98
Change at FUV4; Social functioning1.97 ± 27.351.06 ± 32.12
Change at FUV5; Social functioning1.79 ± 26.720.00 ± 33.79
Change at FUV6; Social functioning1.52 ± 29.2710.00 ± 14.91
Change at FUV7; Social functioning-2.56 ± 23.4233.33
Change at FUV8; Social functioning-10.00 ± 22.3633.33
Change at FUV9; Social functioning-25.00 ± 35.36—
Baseline; Global health status/QoL63.02 ± 21.4567.39 ± 22.17
Change at C1D1; Global health status/QoL0.0 ± 0.06.34 ± 18.41
Change at C2D1; Global health status/QoL2.73 ± 21.695.35 ± 20.14
Change at C3D1; Global health status/QoL2.34 ± 24.662.21 ± 23.58
Change at C4D1; Global health status/QoL3.84 ± 22.267.05 ± 21.05
Change at C5D1; Global health status/QoL7.36 ± 24.207.18 ± 21.94
Change at C6D1; Global health status/QoL4.25 ± 25.005.90 ± 25.16
Change at STC/EW; Global health status/QoL4.32 ± 26.206.51 ± 23.22
Change at EoCTR; Global health status/QoL6.10 ± 23.657.66 ± 24.11
Change at FUV1; Global health status/QoL5.91 ± 24.577.01 ± 25.01
Change at FUV2; Global health status/QoL6.94 ± 24.814.50 ± 26.51
Change at FUV3; Global health status/QoL4.80 ± 25.306.32 ± 27.36
Change at FUV4; Global health status/QoL7.35 ± 26.776.38 ± 27.60
Change at FUV5; Global health status/QoL4.46 ± 23.894.39 ± 18.08
Change at FUV6; Global health status/QoL1.01 ± 24.005.00 ± 7.45
Change at FUV7; Global health status/QoL8.33 ± 25.6916.67
Change at FUV8; Global health status/QoL6.67 ± 16.038.33
Change at FUV9; Global health status/QoL0.00 ± 0.00—
SecondaryChange From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score

The EORTC QLQ-CLL16 module is designed for participants with Stage 0 to Stage 4 CLL. It is composed of 16 questions and there are four multi-item scales on Fatigue (2 items), Treatment-related side effects (TRSE, 4 items), Disease-related symptoms (DRS, 4 items), and Infection (4 items); and two single-item scales on social activities and future health worries. Multi-item scales score are reported and the total score for each multi-item scale was transformed to result in a total score range of 0 to 100, where higher score = poor HRQoL.

Time frame:
Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days
Reported as:
Mean · units on a scale
Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score
units on a scaleBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Baseline; TRSE14.29 ± 13.959.42 ± 8.80
Change at C1D1; TRSE0.0 ± 0.00.12 ± 10.10
Change at C2D1; TRSE1.62 ± 13.820.62 ± 12.76
Change at C3D1; TRSE-0.26 ± 13.761.98 ± 14.72
Change at C4D1; TRSE-0.49 ± 13.970.52 ± 11.87
Change at C5D1; TRSE-0.51 ± 14.570.64 ± 10.02
Change at C6D1; TRSE0.46 ± 15.51-0.13 ± 10.04
Change at STC/EW; TRSE0.81 ± 18.110.13 ± 10.76
Change at EoCTR; TRSE-0.88 ± 16.060.26 ± 12.61
Change at FUV1; TRSE-1.20 ± 14.871.19 ± 12.24
Change at FUV2; TRSE-1.70 ± 15.282.65 ± 14.03
Change at FUV3; TRSE-2.08 ± 12.64-0.13 ± 13.70
Change at FUV4; TRSE-1.97 ± 12.762.84 ± 15.18
Change at FUV5; TRSE-2.68 ± 11.021.32 ± 10.49
Change at FUV6; TRSE-1.01 ± 12.10-1.67 ± 3.73
Change at FUV7; TRSE2.56 ± 22.67-8.33
Change at FUV8; TRSE1.67 ± 13.690.00
Change at FUV9; TRSE8.33 ± 11.79—
Baseline; DRS19.57 ± 16.8116.95 ± 17.37
Change at C1D1; DRS0.0 ± 0.0-2.74 ± 16.18
Change at C2D1; DRS-3.33 ± 16.05-4.77 ± 16.84
Change at C3D1; DRS-4.77 ± 16.49-3.35 ± 17.48
Change at C4D1; DRS-6.03 ± 16.51-5.12 ± 17.72
Change at C5D1; DRS-5.90 ± 16.73-4.79 ± 17.50
Change at C6D1; DRS-6.40 ± 17.26-5.30 ± 16.72
Change at STC/EW; DRS-5.80 ± 18.52-6.51 ± 18.45
Change at EoCTR; DRS-6.57 ± 17.21-5.86 ± 20.38
Change at FUV1; DRS-6.55 ± 15.73-5.82 ± 19.20
Change at FUV2; DRS-8.63 ± 14.39-3.57 ± 18.31
Change at FUV3; DRS-7.37 ± 14.88-3.76 ± 19.25
Change at FUV4; DRS-8.55 ± 18.56-2.66 ± 20.49
Change at FUV5; DRS-8.33 ± 16.13-2.19 ± 19.41
Change at FUV6; DRS-6.31 ± 16.01-3.33 ± 13.94
Change at FUV7; DRS-15.38 ± 20.08-8.33
Change at FUV8; DRS-10.00 ± 16.03-8.33
Change at FUV9; DRS-4.17 ± 5.89—
Baseline; Fatigue28.76 ± 24.6621.74 ± 20.67
Change at C1D1; Fatigue0.0 ± 0.0-2.24 ± 20.29
Change at C2D1; Fatigue-2.55 ± 22.86-5.47 ± 21.40
Change at C3D1; Fatigue-2.83 ± 25.17-3.17 ± 23.73
Change at C4D1; Fatigue-3.18 ± 23.23-4.17 ± 22.02
Change at C5D1; Fatigue-2.38 ± 27.52-4.36 ± 20.89
Change at C6D1; Fatigue-2.66 ± 26.35-2.31 ± 21.42
Change at STC/EW; Fatigue-3.11 ± 28.64-4.69 ± 21.30
Change at EoCTR; Fatigue-6.69 ± 26.78-3.97 ± 24.27
Change at FUV1; Fatigue-6.37 ± 26.61-4.23 ± 22.99
Change at FUV2; Fatigue-6.64 ± 24.55-1.85 ± 24.70
Change at FUV3; Fatigue-5.79 ± 23.29-2.42 ± 23.73
Change at FUV4; Fatigue-9.65 ± 26.84-0.35 ± 25.18
Change at FUV5; Fatigue-6.55 ± 25.563.51 ± 23.95
Change at FUV6; Fatigue-5.05 ± 24.823.33 ± 24.72
Change at FUV7; Fatigue-10.26 ± 30.08-33.33
Change at FUV8; Fatigue-6.67 ± 19.000.00
Change at FUV9; Fatigue-8.33 ± 11.79—
Baseline; Infection15.92 ± 17.6314.01 ± 18.99
Change at C1D1; Infection0.0 ± 0.0-2.24 ± 20.03
Change at C2D1; Infection-0.02 ± 19.98-3.61 ± 21.72
Change at C3D1; Infection-1.66 ± 19.21-1.32 ± 20.48
Change at C4D1; Infection-1.44 ± 22.07-3.13 ± 21.28
Change at C5D1; Infection-1.91 ± 24.00-2.56 ± 23.47
Change at C6D1; Infection-1.09 ± 20.66-2.95 ± 20.54
Change at STC/EW; Infection-0.12 ± 23.28-1.69 ± 23.34
Change at EoCTR; Infection-0.55 ± 21.73-3.44 ± 25.78
Change at FUV1; Infection1.08 ± 18.77-2.65 ± 26.51
Change at FUV2; Infection0.05 ± 23.29-0.53 ± 25.74
Change at FUV3; Infection-1.90 ± 16.97-0.54 ± 26.48
Change at FUV4; Infection-4.24 ± 16.710.53 ± 25.56
Change at FUV5; Infection-4.51 ± 22.667.46 ± 27.20
Change at FUV6; Infection-1.60 ± 18.908.33 ± 15.59
Change at FUV7; Infection-0.43 ± 21.84-16.67
Change at FUV8; Infection8.89 ± 23.36-25.00
Change at FUV9; Infection-2.78 ± 3.93—
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE, v4.0)

Time frame:
From signing of informed consent form up to approximately 8 years 5 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
Adverse Events185194
Serious Adverse Events84101
SecondaryNumber of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs)

An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A SAE is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. TLS and IRRs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening; Grade 5 = Death. A higher grade indicates a worse outcome.

Time frame:
From signing of informed consent form up to approximately 8 years 5 months
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs)
ParticipantsBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main Study
TLS26
IRRs104
Other pre-specifiedChange From Baseline in Lymphocyte Subset Counts at Specified Time Points
Time frame:
Baseline, C4D14-28, Study Treatment Completion/Early Withdrawal (STC/EW, up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and at FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days

Results for this outcome have not been posted.

Post-hocEuro QoL 5 Dimension (EQ-5D) Questionnaire Score
Time frame:
Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days

Results for this outcome have not been posted.

Adverse events

Collected over From signing of informed consent form up to approximately 8 years 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bendamustine + Rituximab Main Study84/188 (44.7%)84/188 (44.7%)177/188 (94.1%)
Venetoclax + Rituximab Main Study60/194 (30.9%)101/194 (52.1%)190/194 (97.9%)
Bendamustine + Rituximab Crossover Substudy1/9 (11.1%)5/9 (55.6%)5/9 (55.6%)
Venetoclax + Rituximab Re-Treatment Substudy8/25 (32%)13/25 (52%)9/25 (36%)
Most frequent serious events
Showing 10 of 167
Most frequent serious events
EventBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyBendamustine + Rituximab Crossover SubstudyVenetoclax + Rituximab Re-Treatment Substudy
PneumoniaInfections and infestations15/18819/1941/93/25
NeutropeniaBlood and lymphatic system disorders3/1883/1941/90/25
Abdominal painGastrointestinal disorders0/1881/1941/91/25
Rhinovirus infectionInfections and infestations0/1881/1941/90/25
SepsisInfections and infestations4/1881/1941/90/25
COVID-19Infections and infestations0/1881/1941/91/25
GastroenteritisInfections and infestations0/1880/1941/90/25
Pneumonia pseudomonalInfections and infestations0/1880/1941/90/25
Electrocardiogram QT prolongedInvestigations0/1880/1941/90/25
SARS-CoV-2 test positiveInvestigations0/1880/1941/90/25
Most frequent other events
Showing 10 of 45
Most frequent other events
EventBendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyBendamustine + Rituximab Crossover SubstudyVenetoclax + Rituximab Re-Treatment Substudy
NeutropeniaBlood and lymphatic system disorders84/188120/1943/95/25
DiarrhoeaGastrointestinal disorders31/18878/1940/93/25
NauseaGastrointestinal disorders64/18842/1940/90/25
Upper respiratory tract infectionInfections and infestations28/18845/1940/91/25
ThrombocytopeniaBlood and lymphatic system disorders42/18823/1940/92/25
AnaemiaBlood and lymphatic system disorders40/18828/1941/91/25
Infusion related reactionInjury, poisoning and procedural complications40/18816/1940/90/25
ConstipationGastrointestinal disorders39/18827/1940/90/25
FatigueGeneral disorders39/18835/1940/91/25
CoughRespiratory, thoracic and mediastinal disorders31/18836/1940/90/25

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.

Age, Continuous
Age, Continuous(years)Bendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyTotal
Mean64.4 ± 9.663.9 ± 10.564.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Bendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyTotal
Female4458102
Male151136287
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyTotal
Hispanic or Latino347
Not Hispanic or Latino186186372
Unknown or Not Reported6410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bendamustine + Rituximab Main StudyVenetoclax + Rituximab Main StudyTotal
American Indian or Alaska Native000
Asian4610
Native Hawaiian or Other Pacific Islander000
Black or African American202
White178181359
More than one race000
Unknown or Not Reported11718
08

Study locations

111 sites
  • University of California San Diego Medical Center
    La Jolla, California 92093-5354, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Memorial Sloan Kettering Cancer Center; Clinical Trials Office
    New York, New York 10021, United States
  • Perlmutter Cancer Center NYU Langone Health
    New York, New York 10032, United States
  • Huntsman Cancer Institute; University of Utah
    Salt Lake City, Utah 84112, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory 2065, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • St George Hospital
    Kogarah, New South Wales, New South Wales 2217, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Monash Medical Centre; Haematology
    Melbourne, Victoria 3168, Australia
  • Slade Health Pharmacy
    Mount Waverley, Victoria 3149, Australia
  • Peter MacCallum Cancer Center
    North Melbourne, Victoria 3051, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • The Perth Blood Institute
    Nedlands, Western Australia 6009, Australia
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, 5020, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Klinik Ottakring
    Wien, 1160, Austria
  • ZNA Antwerpen; Department Hematology
    Antwerpen, 2060, Belgium
  • Cliniques Universitaires Saint-Luc; Hematology
    Bruxelles, 1200, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven; Department Hematology
    Leuven, 3000, Belgium
  • CHU UCL Mont-Godinne
    Mont-godinne, 5530, Belgium
  • AZ Delta (Campus Rumbeke)
    Roeselare, 8800, Belgium
  • Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience
    Calgary, Alberta T2N 2T9, Canada
  • Juravinski Cancer Clinic
    Hamilton, Ontario L8N 3Z5, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Saskatoon City Hospital;Saskatchewan Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Fakultni nemocnice Brno
    Brno, 613 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultní nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha, 100 34, Czechia
  • Herlev Hospital
    Herlev, 2730, Denmark
  • Rigshospitalet
    København Ø, 2100, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Sjællands Universitetshospital, Roskilde
    Roskilde, 4000, Denmark
  • Sygehus Lillebælt, Vejle
    Vejle, 7100, Denmark
  • Hôpital Morvan
    Brest, 29609, France
  • Centre Hospitalier Départemental Les Oudairies
    La Roche sur Yon, 85925, France
  • Hopital Claude Huriez - CHU Lille
    Lille, 59037, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation
    Nantes, 44093, France
  • Hopital Robert Debre
    Paris, 75019, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • CHU Poitiers - Hopital La Miletrie
    Poitiers, 86000, France
  • CHU de Rennes - Hopital de Pontchaillo
    Rennes, 35033, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
    Toulouse, 31059, France
  • CHU Tours - Hôpital Bretonneau
    Tours, 37044, France
  • Hôpital de Brabois Adultes
    Vandoeuvre-les-nancy, 54511, France
  • Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Semmelweis Egyetem
    Budapest, 1088, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Debreceni Egyetem Klinikai Központ; B?rgyógyászati Klinika
    Debrecen, 4012, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Pecs, 7624, Hungary
  • Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp.
    Szeged, 6720, Hungary
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology
    Torino, Abruzzo 10126, Italy
  • Azienda Ospedaliero Universitaria San Martino
    Genova, Liguria 16132, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    Bergamo, Lombardia 24127, Italy
  • Ospedale San Raffaele
    Milano, Lombardia 20132, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; SC Farmacia Ospedale
    Milano, Lombardia 20162, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti
    Torrette Di Ancona, Marche 60126, Italy
  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
    Bari, Puglia 70124, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Florence, Toscana 50134, Italy
  • Azienda Ospedaliera Di Padova
    Padova, Veneto 35128, Italy
  • Seoul National University Bundang Hospital
    Seongnam-si, 463-707, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • The Catholic University of Korea Seoul St. Mary?s Hospital
    Seoul, 6591, Korea, Republic of
  • Amsterdam UMC, Locatie VUMC; Neurology
    Amsterdam, 1081 HV, Netherlands
  • Amsterdam UMC Location AMC
    Amsterdam, 1105 AZ, Netherlands
  • Albert Schweitzer Ziekenhuis, Dordwijk; Internal Medicine, Hemato-Oncology
    Dordrecht, 3318 AT, Netherlands
  • Medisch Spectrum Twente
    Enschede, 7512 KZ, Netherlands
  • Leids Universitair Medisch Centrum; Cardiology
    Leiden, 2333 ZA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3000 CA, Netherlands
  • UMC Utrecht
    Utrecht, 3508, Netherlands
  • North Shore Hospital; Haematolgy
    Auckland, 1309, New Zealand
  • Middlemore Hospital
    Auckland, New Zealand
  • Christchurch Hospital NZ
    Christchurch, 8011, New Zealand
  • Baxter Healthcare
    Mount Wellington, 1060, New Zealand
  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie
    Chorzow, 41-500, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
    Lodz, 93-513, Poland
  • Szpital Wojewodzki w Opolu
    Opole, 45-061, Poland
  • MTZ Clinical Research Sp. z o.o.
    Warszawa, 02-106, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1
    Zabrze, 44803, Poland
  • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
    Moscow, Moskovskaja Oblast 115478, Russian Federation
  • SRI of Hematology and Transfusiology
    Sankt-peterburg, Sankt Petersburg 191024, Russian Federation
  • North-West Federal Medical Research Center n.a. V.A. Almazov
    St. Petersburg, Sankt Petersburg 197341, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • BHI of Omsk region Clinical Oncology Dispensary
    Omsk, 644013, Russian Federation
  • Complejo Hospitalario de Navarra
    Pamplona, Navarra 31008, Spain

Showing the first 100 of 111 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clin Drug Investig. 2022 Aug;42(8):657-668. doi: 10.1007/s40261-022-01172-4. Epub 2022 Jul 13. PubMed 35829925 ↗
  • Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014. PubMed 35605176 ↗
  • Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28. PubMed 32986498 ↗
  • Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3. PubMed 30523712 ↗
  • Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. PubMed 29562156 ↗
  • Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. AAPS J. 2016 Sep;18(5):1192-1202. doi: 10.1208/s12248-016-9927-9. Epub 2016 May 27. PubMed 27233802 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in May 2017, 37 months.

Results were first posted in Oct 2018, 1 year 4 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 37 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 9, 2013
StartActual
Mar 17, 2014
Primary completionActual
May 8, 2017
CompletionActual
Aug 3, 2022
Results first posted
Oct 1, 2018
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02005471
Lead sponsor
Hoffmann-La Roche
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Mar 17, 2014
Primary completion
May 8, 2017
Completion
Aug 3, 2022
Results posted
Oct 1, 2018
Last update
Oct 17, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion